Status:Ongoing

Find Out More
The diagnosis and treatment of Chlamydia Trachomatis and Neisseria Gonorrhea in Woman to prevent adverse neonatal consequences (Maduo/STI Study)

Status:Ongoing

Find Out More
The diagnosis and treatment of Chlamydia trachomatis and Neisseria gonorrhoeae in pregnant women to prevent adverse neonatal consequences.

Status:Ongoing

Find Out More
The FACET Study: Family Dynamics and Child Neurodevelopment in Botswana

Status:Ongoing

Find Out More
Tshilo Dikotla Study: Metabolic Outcomes of Children HIV/ARV- Exposed Uninfected in Botswana

Status:Ongoing

Find Out More
Understanding the Mechanisms of Adverse Birth Outcomes in Botswana

Status:Ongoing

Find Out More
Virologic and Molecular characterization of HIV-1Strains in non-citizens in Botswana

Status:Ongoing

Find Out More
Virologic responses among people with HIV on dolutegravir-based first line therapy in Botswana

Status:Ongoing

Find Out More
Assessing barriers and facilitators to improving prenatal supplementation and preconception fortification in Botswana – a qualitative study

Status:Ongoing

Find Out More
CoVPN 5001: A Prospective Study of Acute Immune Responses to SARS-CoV-2 Infection.

Status:Ongoing

Find Out More
Evaluating a Group-Based Intervention to Improve Mental Health and ART Adherence Among Youth Living with HIV in Low Resource Settings (IMPAACT 2016)

Status:Ongoing

Find Out More
HPTN 084: A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women

Status:Ongoing

Find Out More
HVTN 703/HPTN 081 (AMP Study): A phase 2b study to evaluate the efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection in women in Sub- Saharan Africa.

Status:Ongoing

Find Out More
HVTN805/HPTN093: Antiretroviral analytical treatment interruption (ATI) to assess immunologic and virologic responses in participants who initiated ART in early HIV infection after having received VRC01 or placebo in HVTN 703/HPTN 081.

Status:Ongoing

Find Out More
IMPAACT 2005

Status:Ongoing

Find Out More
IMPAACT 2017 - Phase I/II Study of the Safety, Acceptability, Tolerability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Long-Acting Injectable Rilpivirine in Virologically Suppressed HIV-Infected Children and Adolescents

Status:Ongoing

Find Out More
IMPAACT 2019 – Phase I/II Study of the Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less than 12 Years of Age

Status:Ongoing

Find Out More
IMPAACT 2042: Phase I/II Trial to Evaluate the Impact of Three Broadly Neutralizing Antibodies or Analytic Treatment Interruption on Viral Reservoir, Immune Function, and Maintenance of HIV Suppression in Early-Treated Children in Botswana

Status:Ongoing

Find Out More
Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern: CoVPN 3008

Status:Ongoing

Find Out More
Open-Label, Single-Arm, Phase 3B Study of the Incidence of Severe COVID-19 and Adverse Events Following AZD1222 COVID-19 Vaccination in Botswana Against SARS-CoV-2

Status:Ongoing

Find Out More
P1093 - Phase I/II, Multi-Centre, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of Dolutegravir, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents